Literature DB >> 1334552

Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists.

P W Schiller1, T M Nguyen, G Weltrowska, B C Wilkes, B J Marsden, C Lemieux, N N Chung.   

Abstract

Opioid peptide analogs consisting entirely of aromatic amino acid residues and containing conformationally restricted phenylalanine derivatives in position 2 of the peptide sequence were synthesized and pharmacologically characterized in vitro. Both diastereoisomers of H-Tyr-(D or L)-NMePhe-Phe-Phe-NH2 (NMePhe is N alpha-methylphenylalanine) were mu-receptor-selective, were full agonists in the mu-receptor-representative guinea pig ileum assay, and were partial agonists in the mouse vas deferens assay, with the L-NMePhe2 analog displaying somewhat higher intrinsic activity than the D-NMePhe2 analog. Further conformational restriction at position 2 in the sequence, as achieved through substitution of D- or L-tetrahydro-3-isoquinoline carboxylic acid (Tic), produced a configuration-dependent differential effect on receptor selectivity and intrinsic activity, leading to a potent mu-selective mu agonist (the D-Tic2 analog) with increased intrinsic activity in the mouse vas deferens assay and to a potent delta-selective delta antagonist (the L-Tic2 analog). These results demonstrate that imposition of conformational constraints in a peptide not only may alter receptor selectivity but also may decrease, totally abolish, or even enhance intrinsic activity. The tetrapeptide H-Tyr-Tic-Phe-Phe-NH2 was a moderately potent full agonist in the guinea pig ileum assay and, thus, represents a compound with mixed mu-agonist/delta-antagonist properties. The corresponding peptide with a free C-terminal carboxyl group H-Tyr-Tic-Phe-Phe-OH showed high delta-receptor affinity (Ki delta = 1.2 nM), unprecedented delta selectivity (Ki mu/Ki delta = 1410), high potency as delta antagonist (Ke = 3-8 nM against various delta agonists in the mouse vas deferens assay) and, unlike other delta antagonists, had no mu-antagonist properties. The tripeptides H-Tyr-Tic-Phe-OH and H-Tyr-Tic-Phe-NH2 were also delta antagonists.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334552      PMCID: PMC50659          DOI: 10.1073/pnas.89.24.11871

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice.

Authors:  E E Abdelhamid; M Sultana; P S Portoghese; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

2.  Dynorphin is a specific endogenous ligand of the kappa opioid receptor.

Authors:  C Chavkin; I F James; A Goldstein
Journal:  Science       Date:  1982-01-22       Impact factor: 47.728

3.  ICI 174864: a highly selective antagonist for the opioid delta-receptor.

Authors:  R Cotton; M G Giles; L Miller; J S Shaw; D Timms
Journal:  Eur J Pharmacol       Date:  1984-01-27       Impact factor: 4.432

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Dermorphin analogues carrying an increased positive net charge in their "message" domain display extremely high mu opioid receptor selectivity.

Authors:  P W Schiller; T M Nguyen; N N Chung; C Lemieux
Journal:  J Med Chem       Date:  1989-03       Impact factor: 7.446

6.  Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites.

Authors:  V Erspamer; P Melchiorri; G Falconieri-Erspamer; L Negri; R Corsi; C Severini; D Barra; M Simmaco; G Kreil
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

7.  Reduction in opiate receptor reserve in morphine tolerant guinea pig ilea.

Authors:  C Chavkin; A Goldstein
Journal:  Life Sci       Date:  1982 Oct 18-25       Impact factor: 5.037

8.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

9.  Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity.

Authors:  P W Schiller; G Weltrowska; T M Nguyen; C Lemieux; N N Chung; B J Marsden; B C Wilkes
Journal:  J Med Chem       Date:  1991-10       Impact factor: 7.446

10.  A cyclic enkephalin analog with high in vitro opiate activity.

Authors:  J DiMaio; P W Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  41 in total

1.  Molecular modeling study of the differential ligand-receptor interaction at the mu, delta and kappa opioid receptors.

Authors:  M Filizola; M Carteni-Farina; J J Perez
Journal:  J Comput Aided Mol Des       Date:  1999-07       Impact factor: 3.686

2.  Stereochemical requirements for receptor recognition of the mu-opioid peptide endomorphin-1.

Authors:  M G Paterlini; F Avitabile; B G Ostrowski; D M Ferguson; P S Portoghese
Journal:  Biophys J       Date:  2000-02       Impact factor: 4.033

3.  Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.

Authors:  Gianfranco Balboni; Valentina Onnis; Cenzo Congiu; Margherita Zotti; Yusuke Sasaki; Akihiro Ambo; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Claudio Trapella; Severo Salvadori
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

4.  The role of crystallography in drug design.

Authors:  Jeffrey R Deschamps
Journal:  AAPS J       Date:  2005-12-07       Impact factor: 4.009

Review 5.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

6.  Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore.

Authors:  Gianfranco Balboni; Severo Salvadori; Claudio Trapella; Brian I Knapp; Jean M Bidlack; Lawrence H Lazarus; Xuemei Peng; John L Neumeyer
Journal:  ACS Chem Neurosci       Date:  2010-02-17       Impact factor: 4.418

7.  Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1).

Authors:  Gianfranco Balboni; Remo Guerrini; Severo Salvadori; Lucia Negri; Elisa Giannini; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

8.  Dual labeled peptides as tools to study receptors: nanomolar affinity derivatives of TIPP (Tyr-Tic-Phe-Phe) containing an affinity label and biotin as probes of delta opioid receptors.

Authors:  Jane V Aldrich; Vivek Kumar; Thomas F Murray; Wei Guang; Jia Bei Wang
Journal:  Bioconjug Chem       Date:  2009-02       Impact factor: 4.774

Review 9.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

10.  Solid Phase Synthesis and Application of Labeled Peptide Derivatives: Probes of Receptor-Opioid Peptide Interactions.

Authors:  Jane V Aldrich; Vivek Kumar; Bhaswati Dattachowdhury; Angela M Peck; Xin Wang; Thomas F Murray
Journal:  Int J Pept Res Ther       Date:  2008-12-01       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.